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Pulmonary arterial hypertension (PAH) encompasses a number of diseases responsible for
a specific set of hemodynamic findings during right heart catheterization. During initial
workup, pulmonary vasodilator testing is performed. A positive acute pulmonary vasodilator
test predicts better survival and response to calcium channel blocker (CCB) therapy.
There is lack of consensus on the preferred agent for determining acute pulmonary vasor-
eactivity. The ACCP guidelines and the 4th World Symposium on Pulmonary Hypertension
support the use of intravenous epoprostenol or nitric oxide (NO) as the preferred agents for
pulmonary vasodilator testing.
A decrease in the mean pulmonary artery pressure by at least 10 mmHg to reach an absolute
value of 40 mmHg or less without a decrease in cardiac output is currently considered a positive
pulmonary vasodilator test. A positive test by the current recommended criteria is observed in
about 10-15% of patients with idiopathic PAH. Approximately half of these patients will expe-
rience long-term benefits with CCBs. A positive test may select patients with an earlier or less
aggressive form of disease, which may carry a better prognosis. A positive vasodilator test is
observed very infrequently in patients with pulmonary arterial hypertension other than idio-
pathic PAH or anorexigen associated PAH.al hypertension; IPAH, Idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial
sistance; SVR, systemic vascular resistance; CO, cardiac output; PAOP, pulmonary artery occlusion
saturation; CCBs, calcium channel blockers; NO, inhaled nitric oxide; ppm, parts per million; IV,
of Chest Physicians; NYHA, New York Heart Association; WHO, World Health Organization.
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therapy in patients with PAH, while identifying the gaps in knowledge concerning this
diagnostic procedure.
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Pulmonary hypertension is a condition characterized by an
elevated mean pulmonary artery pressure (mPAP) due to
diverse etiologies. The World Health Organization (WHO)
classification divides pulmonary hypertension into five
categories depending on histopathology, clinical presenta-
tion, diagnostic findings and response to treatment.1e3 The
first category, termed pulmonary arterial hypertension
(PAH), encompasses a number of diseases responsible for
a specific set of hemodynamic findings during right heart
catheterization. These findings include a mPAP of 25 mmHg
or greater at rest, or 30 mmHg or higher with exercise, in
combination with a pulmonary vascular resistance (PVR) ofmore than 3 Wood units and a pulmonary artery occlusion
pressure (PAOP) of 15 mmHg or less.4e6 The 4th World
Symposium on Pulmonary Hypertension recommended
a mPAP of 25 mmHg of greater as the only criterion to
define pulmonary hypertension, eliminating the exercise
and PVR components.7
Right heart catheterization is required for the diagnosis
of PAH. In addition, it facilitates the exclusion of pulmonary
venous hypertension and intracardiac shunts, helps assess
the severity of hemodynamic impairment, provides prog-
nostic information and assists in guiding appropriate
therapy.4,8e10 Right heart catheterization in patients with
PAH is safe, especially when done in specialized
centers.8,11,12
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Indications
There are several reasons why pulmonary vasodilator
testing may be performed during right heart catheteriza-
tion. Firstly, in congenital heart disease with severe PAH, it
is helpful in management and treatment. Secondly, in
candidates for heart transplantation, pulmonary vasodi-
lator testing helps evaluate the need for concomitant lung
transplantation. Lastly, in PAH, it is helpful in selection of
the appropriate medical therapy.13
Pulmonary vasodilator testing establishes the relative
contribution of reversible vasoconstriction versus fixed
stenosis in patients with PAH. If the magnitude of the
reversible vasoconstrictive component is significant, it
identifies patients who may derive benefits from long-term
use of calcium channel blocker (CCB) therapy.14
A significant proportion of patients who have a positive
pulmonary vasodilator test benefit from the use of CCB
therapy, while those who have a negative pulmonary vaso-
dilator test, not only are unlikely to benefit from CCB
therapy, but CCB therapy can cause deleterious adverse
reactions.15e17 The empiric use of CCBs in PAH is strongly
discouraged as it may cause systemic hypotension, wors-
ening right heart failure and death.8,11,18,19 The mechanisms
for the deleterious adverse reactions to CCB remain uncer-
tain. Potential explanations are depression in the myocardial
contractility, activation of endogenous neurohormonal
systems which have an adverse effect on cardiovascularTable 1 Recommendations and level of evidence, for undergoing
presence of a positive test (modified from the ACCP 2004 guidelin
Pulmonary Hypertension16,19).
Recommendations Quality
Patients with IPAH should undergo pulmonary
vasodilator testing using short-acting agent such
as IV epoprostenol or NO.
Patients with PAH associated with underlying
processes, such as scleroderma or congenital
heart disease, should undergo pulmonary
vasodilator testing.
Exper
Patients with PAH should undergo pulmonary
vasodilator testing by an experienced physician in
the management of pulmonary vascular diseases.
Exper
Patients with IPAH demonstrating a favorable acute
response to vasodilator, should be considered
candidates for a trial with CCBs (amlodipine,
diltiazem or nifedipine).
L
Patients with PAH associated with underlying
processes such us scleroderma or congenital heart
diseases, demonstrating a favorable acute response
to vasodilator, should be considered for a trial
with CCBs.
Exper
In patients with PAH, CCBs should not be used
empirically to treat PH in the absence of
demonstrated acute vasoreactivity.
Exper
A, strong recommendation; B, moderate recommendation; E/A, str
moderate recommendation on the basis of expert opinion only; E/C,performance such as renin-angiotensin system, and hypo-
tension leading to reduced coronary perfusion and as a result
ischemic myocardial dysfunction.20
Pulmonary vasodilator testing is not necessary in
patients who are not candidates to receive CCBs or who are
already benefiting from them.21 CCBs would not be indi-
cated in patients with right heart failure or hemodynamic
instability.6
The presence of acute pulmonary vasoreactivity predicts
response to CCBs and decreases the incidence of life-
threatening adverse effects when using chronic CCB ther-
apy.22e24 Conflicting evidence exists regarding the value of
a positive pulmonary vasodilator test to predict better
survival.24,25 Although a better prognosis was reported in
patients with acute pulmonary vasoreactivity,23,26 Ruben-
fire et al., found no difference in 10-year survival in PAH
patients who had a positive pulmonary vasodilator test with
inhaled NO.25
Recommendations and level of evidence for undergoing
vasodilator testing and treatment in the presence of
pulmonary vasoreactivity have been outlined by the ACCP
in 2004 and the 4th Word Symposium on Pulmonary Hyper-
tension16,19 (Table 1).
Criteria for a positive test
Multiple criteria for a positive pulmonary vasodilator test
have been suggested (Table 2). A decrease of the mPAP of
at least 10 mmHg to reach an absolute value of 40 mmHg or
less without a decrease in cardiac output is currentlypulmonary vasodilator testing and receiving treatment in the
es for medical therapy for PAH and 4th World Symposium on
of evidence Benefit Strength of recommendation
Fair Substantial A
t opinion Small/weak E/C
t opinion Substantial E/A
ow Substantial B
t opinion Intermediate E/B
t opinion Substantial E/A
ong recommendation on the basis of expert opinion only; E/B,
weak recommendation on the basis of expert opinion only.
Table 2 Criteria for a positive pulmonary vasodilator test
depending on the study analyzed.
1. Fall in PVR greater than 20%.26
2. Decrease in PVR of more than 20% with preserved or
increased CO and no change or a decrease in the
PVR/SVR ratio.27
3. Decrease in mPAP or PVR greater than 20%.28
4. Fall in both mPAP and PVR of greater than 20%.17
5. Decrease in total pulmonary resistance of 30%.29
6. Reduction in PVR of 50% and mPAP of 33%.30
7. Decrease in mPAP of at least 10 mmHg to an absolute
level below 40 mmHg with preserved or increased
CO.4,6,8,19,22 Current recommended definition of a
positive test.
484 A.R. Tonelli et al.recommended to consider a pulmonary vasodilator test as
positive.4,5,8,16,19,22 It should be noted that patients in
whom the mPAP remains above 40 mmHg despite
a decrease in the mean pulmonary arterial pressure of
10 mmHg or more are not considered responders.
This revised definition of positive pulmonary vasodilator
test, replaced the older definition that considered a test
positive when the mPAP and PVR decreased by at least
20%.13 The change in the definition was motivated by the
poor identification of patients that experience sustained
benefits from CCB therapy.4,8,19,22 In other words, a positive
test by the older definition, includes a relatively large
percentage of patients who will experience long-term
failure with CCBs.10,22,24 Sustained benefit with CCBs is
defined by the improvement of dyspnea to New York Heart
Association (NYHA) class II or less in concert with sustained
hemodynamic improvement after a year of treatment.8,22
Problems associated with the older definition derive
from the finding that PAP and PVR vary spontaneously at
rest. The mean variation is approximately 8% in mPAP and
13% in PVR. The variations directly correlate with the
severity of disease. To attribute changes with 95% confi-
dence to drug effect, the mean change in mPAP and PVR
should be 22% and 36%, respectively.31
A positive pulmonary vasodilator test based on
a decrease in PVR of at least 20%, in IPAH patients that
received CCB treatment, did not predict the clinical course
of the disease or altered survival.32
Older versus current criteria for a positive
vasodilator test
The current criteria derive from a retrospective analysis of
557 IPAH patients who received long-term treatment with
CCBs after a positive pulmonary vasodilator test by the
older definition. Of 12.6% of the patients who manifested
acute pulmonary vasoreactivity by the older definition, only
half (6.8%) experienced long-term (at least 1 year of follow-
up) improvement with the use of calcium channel blockers.
Long-term CCB responders had less severe disease, more
pronounced fall and lower levels of mPAP and PVR. Inter-
estingly, the mPAP reached during acute vasodilatory test
was less than 40 mmHg in the majority of patients consid-
ered long-term CCB responders.22A retrospective study on hemodynamic data of 34 idio-
pathic PAH patients using NO tested the traditional and the
revised criteria for pulmonary vasodilator testing. The
number of responders was higher using the older criteria
(26.5% versus 17.6%). An explanation as to why the revised
criteria better predict long-term responders to CCBs was
indicated by the presence of a more favorable hemody-
namic profile in the responders by the revised criteria
(higher CO and lower PVR).33
The new criteria for a positive pulmonary vasodilator
test improve the specificity for predicting long-term
response to CCB treatment, thus avoiding adverse effects
of CCB treatment in patients who will not be long-term
responders to CCBs. According to the results of the study by
Sitbon et al., the sensitivity, specificity, positive and
negative predictive values of pulmonary vasodilator
testing, using the new criteria, are 69%, 87%, 78% and 81%,
respectively.22
Frequency of a positive test
Most of the studies that tested pulmonary vasoreactivity
have been done in patients with IPAH, a progressive
disorder with grim prognosis as it leads to right heart failure
and ultimately death.5,9,34 IPAH is characterized by
pulmonary artery medial hypertrophy, intimal proliferation
and fibrosis, as well as plexiform and thrombotic lesions of
the small pulmonary arteries.35e37 The percentage of
positive tests depends on the criteria used (Table 3) and it
is observed in about 10-15% of patients using the current
criteria.43e45 Half of the patients with a positive test will
experience long-term benefits with CCBs22,46 (Fig. 1),
presumably due to lack of effect of CCBs in patients whose
vascular changes are related to intimal proliferation,
fibrosis and thrombosis.
In a study by Zimmerman et al., utilizing the current
criteria, a positive pulmonary vasodilator test was observed
in 9.5% of idiopathic and heritable PAH patients, and it was
more commonly observed in female patients with lower
body mass index and less severe hemodynamic profile.45
Children with IPAH have a higher frequency of positive
vasodilator tests than adults, possibly explained by a more
severe concentric laminar intimal fibrosis in the latter
group.47,48 Consequently, more children than adults can be
treated with CCBs. A study by Barst et al. included 74
children (7 4 years) with IPAH. Approximately 40% were
responders (defined as a decrease in 20% or more in the
mean pulmonary artery pressure without changes in the CO
and no variation or a decrease in the PVR/SVR ratio). Of the
responders, 52% had long-term (63 43 months) clinical
and hemodynamic response with the use of CCBs.27
Agents used
In 1958, Wood administered acetylcholine in 6 patients with
idiopathic pulmonary arterial hypertension (IPAH) and
noted a profound fall in the pulmonary pressure and resis-
tance with increase in cardiac output (CO), suggesting the
presence of a powerful vasoconstrictive factor.49 Since that
time, drugs for acute vasodilator testing have been chosen
based on selectivity for the pulmonary circulation and short
Table 3 Studies that evaluated the use of pulmonary vasodilator testing in patients with PAH.
Author, Year Number of
patients
Type of PAH Definition of positive
vasodilator test
Agent used % of positive
tests
Implications
Rich et al., 199138 47 Idiopathic >20% Reduction in PVR and mPAP CCB PO 32% No acute mortality or serious morbidity
noted with high doses of CCBs, when right
heart failure is excluded.
>20% Reduction in PVR CCB PO 40%
Rich et al., 199217 64 Idiopathic >20% Reduction in PVR and mPAP CCB PO 27% Better survival in responders treated
with CCBs.
Schrader et al.,
199239
15 PAH >20% Reduction in PVR Adenosine IV 80% Greater decrease in PVR, without changes in
mPAP, with adenosine.CCB PO 47%
Groves et al., 199314 44 Idiopathic >30% Decrease in PVR and
>10% decrease in mPAP
Epoprostenol IV 30% A positive test predicted response to oral
CCB therapy
Sitbon et al., 199529 35 PAH > 30% Decrease in PVR Epoprostenol IV 37% Both drugs produced similar vasodilator
response.NO 37%
McLaughlin
et al., 199840
27 Idiopathic >20% Decrease in PVR Adenosine IV 70% Long-term effects of epoprostenol
exceeded the acute response to adenosine.
Sitbon et al., 199815 33 Idiopathic >20% Decrease in PVR and mPAP NO 30% High correlation between NO and acute CCB
response. NO is safer.CCB PO 27%
Ricciardi
et al., 19982
17 Idiopathic >20% Decrease in PVR or mPAP NO 41% High correlation between NO and acute CCB
responseCCB PO 47%
Morales-Blanhir
et al., 200424
27 PAH 30% Decrease in PVR and
20% reduction in mPAP
Epoprostenol IV 26% 15% had a positive vasodilator response with
both agents.NO 26%
Sitbon et al., 200522 557 PAH >20% Decrease in PVR or mPAP Epoprostenol or NO 12.6% Long-term CCB responders represented 6.8%
of IPAH patients.
Thenappan
et al., 200741
578 PAH 10 mmHg Decrease in mPAP
to 40 mmHg.
Adenosine IV 4.5% Large number of patients was receiving
CCBs despite a negative vasodilator test.
Jing et al., 200942 74 Idiopathic 10 mmHg Decrease in mPAP
to 40 mmHg.
Adenosine IV 11% A positive test predicted response to oral
CCB therapyIloprost inhaled 14%
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Figure 1 Positive pulmonary vasodilator tests and long-term
calcium channel blocker responders in IPAH patients (adapted
from Ref. [22]). Percentages of positive pulmonary vasodilator
tests (decrease in mPAP and PVR of >20%) and long-term CCB
responders are 12.6 and 6.8%, respectively.
486 A.R. Tonelli et al.duration of action, to minimize systemic adverse effects.23
The ideal vasodilator should decrease PVR as well as mPAP,
and increase CO along with mixed venous oxygen
saturation.46
The agents currently recommended to evaluate the
pulmonary vasoresponsiveness include: inhaled nitric
oxide, intravenous adenosine or epoprotenol.7,8,16,43 (Table
4). In addition, inhaled iloprost also has acquired subs-
tantial evidence for this use,42,50 although this agent
is not currently recommended by the most updated
guidelines.6,7
It is important to consider that these agents have
different mechanisms of action and diverse hemodynamic
effects, so that their use may not be interchangeable.44 For
instance, prostaglandin analogs and adenosine increase CO
and postcapillary pressure either directly or indirectly by
inducing systemic vasodilation and reflex tachycardia. On
the contrary, NO does not affect CO or postcapillary pres-
sure.44 Changes in the CO and postcapillary pressure
directly affect mPAP, thus making the interpretation of the
pulmonary vasodilator test more complicated.23,44 As
a result of the above, some patients who show negative
pulmonary vasodilator response to one medication may
fulfill criteria with another agent.44,50
The adverse effect profile also varies among the rec-
ommended agents. Some agents have been associated with
hypotension, worsening right heart failure, and increase in
intrapulmonary shunt.51
There is lack of consensus on the preferred agent for
determining acute pulmonary vasoreactivity.44 The ACCP
guidelines and the 4th World Symposium in Pulmonary
Hypertension support the use of IV epoprostenol or NO as
the preferred agents for pulmonary vasodilator test.6,7,16
Adenosine may be used if neither is available.16 In the
absence of evidence-based guidelines, the ACCF/AHA 2009
Expert Consensus Document on Pulmonary Hypertensionrecommends inhaled NO as the preferred vasodilator agent
and considers IV epoprostenol and adenosine, acceptable
alternatives.6
We include the pulmonary vasodilator test protocol
currently used at the University of Florida (Table 5). We use
NO for three main reasons. Firstly it has almost no adverse
effects when used for a short period of time, secondly the
duration of the test is shorter than when other agents are
used, therefore reducing the catheterization laboratory
time, and lastly the necessary equipment and respiratory
therapists are readily available at our institution.
Inhaled nitric oxide
NO is an odorless gas that selectively vasodilates the
pulmonary arterial circulation and produces minimal
systemic side effects.29,52 NO is a lipid soluble molecule
that rapidly diffuses across the alveolar-capillary
membrane into the pulmonary artery smooth muscle. It
activates soluble guanylate cyclase that in turn increases
the levels of cGMP (cyclic guanosine 3050-monophosphate),
leading to vasodilation. NO half-life is very short, because
when NO reaches the circulation, it is quickly scavenged by
hemoglobin.53,54
In comparison with other agents, this medication does
not affect the CO but enhances ventilation-perfusion
matching by increasing blood flow to well-ventilated areas
of the lung. These properties position NO as one of the
preferred agents to be used during pulmonary vasodilator
testing.
Atz et al. carried out a study in predominantly pediatric
patients with congenital heart disease and PAH, using
oxygen in two concentrations (21% and 100%) alone or
combined with NO (80 ppm). This study showed that NO
mixed with oxygen produced a significant decrease in mPAP
and PVR when compared to O2 alone.
55
The NO concentration in parts per million (ppm), the
duration of the inhalation and the best dilution with oxygen
for pulmonary vasodilator testing has not been standard-
ized. NO doses of 10e80 ppm for up to 15 min are usually
given,28,56 even though a study has shown that the vasodi-
lator response to NO was not dependent upon the NO
concentration. The maximal effect was obtained at 10 ppm
within 2 min of inhalation.29 Hemodynamic measures are
obtained after inhaling NO for 2e6 min.24,28,29,53 As oxygen
can reduce mPAP in patients with PAH (even in the absence
of a hypoxic vasoconstrictor stimulus), NO in 100% O2 is
preferred.57
Adverse effects with inhaled NO at 80 ppm or less are
very rare and include methemoglobinemia, accumulation of
NO2
 and rebound PAH.15,54,58,59 Rebound PAH, manifested
as hypoxemia and systemic hypotension, is unlikely to occur
after sudden discontinuation of NO, when the agent is used
for a brief period of time.60,61 The cost of NO, when used
for a few minutes, is low, provided the delivery system and
gas cylinder are available in the institution.
Epoprostenol
Epoprostenol, given intravenously, has vasodilatory, anti-
aggregative, antiproliferative and anti-inflammatory
actions.62 Its vasodilatory effects are mediated by activa-
tion of the cell surface prostaglandin I receptor that acti-
vates the adenylate cyclase system, increasing intracellular
Table 4 Medications currently recommended for pulmonary vasodilator testing.
Route Initial Dose Maximum
suggested dose
Duration of
each step
Onset of
action
Half-life Adverse effects Considerations
Nitric oxide
on O2
Inhaled
(face mask)
10 ppm 80 ppm 5e10 min Few
seconds
3 min Rebound pulmonar hyper-
tension (unlikely w th short
administration)
Pulmonary edema
pulmonary venous
hypertension.
Practical
Short acting
Few systemic effects
Does not increase shunt or affect CO
Shorter duration of the test
Requires respiratory therapy
Relatively cheap but cylinder and
monitor need to be available
Epoprostenol Intravenous 2
ng/kg/min
12
ng/kg/min
10e15 min Few
minutes
4e6 min Headache, flushing jaw
pain,
nausea, dizziness,
hypotension,
diarrhea.
Unstable at room temperature
IV infusion
Associated with systemic side effects
Increases CO and pulmonary shunt
Longer duration of the test
Expensive
Adenosine Intravenous 50
mg/kg/min
500
mg/kg/min
2 min Few
seconds
5e10 s Systemic hypotens n,
bradycardia, bronc ospasm,
chest pain, AV blo .
Greater availability without the need
of special delivery systems.
Associated with systemic side effects
Increases CO and systemic shunt
Relatively cheap
Iloprost Inhaled 2.5
mg/inh
5
mg/inh
30 min Several
minutes
20e30
min
Headache, flushing jaw
pain,
dizziness, hypoten on, etc.
Practical
Associated with systemic side effects
Longer duration of test
For NO a single step is suggested, as it appears that doses above 20 ppm do not generate greater decreases in the mPAP. For epopro tenol and adenosine increments of 2 ng/kg/min and
50 mg/kg/min are appropriate until adverse symptoms occur or the maximal dose is achieved.
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Table 5 University of Florida pulmonary vasodilator
testing protocol.
1. Confirm indication of the test by reviewing the
patient’s medical records and performing a brief
medical history.
2. Obtain inform consent.
3. Connect patient to ECG, blood pressure and peripheral
oximetry monitors.
4. Using ultrasound cannulate preferably the right
internal jugular vein.
5. Place a pulmonary arterial catheter by fluoroscopic
guidance.
6. Obtain resting right heart, pulmonary and PAOP while
the patient is in supine position and breathing room air
or oxygen to maintain pulse oximetry above 90%. If
PAOP measurement is not reliablea obtain left
ventricular end-diastolic pressure.
7. Measure CO by thermodilution (if severe tricuspid
regurgitation is present, determine CO by Fick meth-
odology). Calculate cardiac index and PVR.
8. Withdraw blood from distal port of pulmonary catheter
for mixed venous O2. If needed obtain oxygen satura-
tions from SVC, IVC and RV.
9. If patient meets criteria for PAH proceed with NO
challenge.
10. Administer NO 20 ppm on 100% O2 for 5 min through
a face mask.
11. Repeat measurements of PAP and CO.
12. Define if patient has a positive pulmonary vasodilator
test.
13. If no need to repeat measurements, end of study.
PAOP, pulmonary artery occlusion pressure; CO, cardiac output;
PVR, pulmonary vascular resistance; SVC, superior vena cava;
IVC, inferior vena cava; RV, right ventricle; NO, nitric oxide;
ppm, parts per million; PAP, pulmonary artery pressure.
a PAOP is considered not reliable when the waveform is
atypical, the oxygen saturation obtained from the distal lumen
while the balloon is inflated is below the one measured in
arterial blood gas analysis or pulse oximetry, and lastly when
there is movement of the catheter tip while on wedge position
during fluoroscopy.
488 A.R. Tonelli et al.cAMP.62 This medication lowers pulmonary and systemic
arterial pressure, and increases heart rate and CO.14,29 The
increase in heart rate and CO occurs regardless of the
pulmonary vasodilatory response.29 When epoprostenol
dilates the pulmonary vasculature, it may increase the
shunt fraction by increasing ventilation-perfusion
mismatch, leading to hypoxemia.
Pulmonary vasodilator testing with epoprostenol is able
to predict long-term response to CCBs. In one of the first
studies, epoprostenol was compared with 5-day CCB chal-
lenge (nZ 44). At one year, 30% of patients on CCBs were
clinically improved and 14% had an associated hemody-
namic improvement. Epoprostenol identified the patients
most likely to benefit from CCB therapy; however, a favor-
able response to epoprostenol does not indicate that all
patients will have a long term response to CCBs.14Raffy et al. tested the acute pulmonary vasodilator
response to epoprostenol in patients with IPAH. Of a total of
91 patients, 10% were highly responsive, defined as
a decrease of more than 50% in PVR. Interestingly, highly
vasoresponsive patients had longer disease development
and higher 2-year survival, suggesting that this group of
patients may have a slower disease progression and there-
fore a better prognosis.26 Indeed, CCB-responsive IPAH may
represent a completely separate subset of PAH with
a different etiology and pathogenesis.
A study of 10 patients with PAH compared epoprostenol
with other vasodilator agents including acetylcholine,
nitroglycerin, isoproterenol, nifedipine, nitroprusside,
phentolamine and hydralazine. The most significant vaso-
dilator responses were achieved after the administration of
epoprostenol, but most importantly, no patients exhibited
a vasodilator response to any medication without showing
a favorable response with epoprostenol.63
Intravenous epoprostenol is usually begun at 1e2.5 ng/
kg/min and increased 1e2.5 ng/kg/min every 5e15 min to
a maximum dose of 10e16 ng/kg/min unless adverse
effects occur.14,26,29,56,57,64 Due to its short half-life, IV
epoprostenol can be safely and rapidly increased to
maximal tolerated doses. Hemodynamic measurements can
be obtained 10e15 min after the maximum tolerated
dose.29
Epoprostenol causes frequent adverse reactions such as
flushing, headache and hypotension.29 This agent should be
avoided in patients known to have pulmonary veno-occlu-
sive disease or pulmonary capillary hemangiomatosis
because severe pulmonary edema and death may occur.65
Indeed many patients are first suspected to have these
variants of PAH because of adverse effects during pulmo-
nary vasodilator testing. In patients with left-sided heart
failure, epoprostenol is unlikely to produce life-threatening
adverse effects during pulmonary vasodilator testing, but
its chronic use has been associated with a strong trend
towards an increased risk of death.66
Iloprost
Iloprost is a prostaglandin analog that can be given intra-
venously or by inhalation. Its inhalation allows intra-
pulmonary selectivity and decreases systemic side effects
as well as ventilation-perfusion mismatch. When iloprost is
inhaled, it directly acts on the adventitial side of the
pulmonary artery wall.62
Inhaled iloprost produces a decrease in the PVR andmPAP
while increasing CO and oxygen saturation in systemic arte-
rial and mixed venous blood.42,57,67 The cumulative dose
usually given is from 5 to 50 mg in 10e15 min through
a nebulizer.42,57 Intravenous iloprost behaves similarly to
epoprostenol but requires a longer study time as it has
a longer half-life compared to epoprostenol.57,68
Jing et al. studied iloprost for pulmonary vasodilator
testing in patients with IPAH. Out of 74 patients, 13.5% had
a positive pulmonary vasodilator test (10 mmHg decrease
in mPAP to 40 mmHg). Patients who had vasoreactivity
were younger with less severe disease. About 50% of the
vasoreactive patients to inhaled iloprost were long term
responders (12 months) to CCBs. Only 2.7% of patients
presented adverse effects with inhaled iloprost, predomi-
nantly cough and hypotension.42
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Adenosine is an easily available, stable and inexpensive
medication which has pulmonary vasodilatory properties.
Its vasodilatory effects are mediated by activation of the
specific cell membrane receptor A2, which results in
increased intracellular cAMP.69 It has a half-life of 5e10 s,
as it is metabolized by adenosine deaminase in erythrocytes
and endothelial cells.70 When given intravenously, the short
half-life allows a relatively higher plasma concentration of
the agent in the pulmonary rather than the systemic
circulation, thus reducing systemic side effects.64
Adenosine lowers PVR and increases cardiac
output.40,42,71 A reduction in mPAP has not consistently
been observed.39,64 It decreases the SVR, but the ratio of
PVR to SVR also decreases, reflecting a preferential vaso-
dilator effect on the pulmonary circulation.42,72 This agent
can also increase the PAOP, right atrial pressure, mPAP and
systemic arterial saturation.71
When given intravenously, adenosine is started at 50e
100 mg/kg/min and increased by 50 mg/kg/min every two
minutes until the patients develops symptom-limiting
adverse effects or the maximal dose is achieved (200e
500 mg/kg/min).39,42,64 Continuous infusions of adenosine
can also be given into the right ventricle or pulmonary
artery, with the objective of reducing the systemic side
effects of the medication.13
Adverse effects, predominantly palpitations and dyspnea
can be observed in almost half of patients receiving adeno-
sine infusion.42 Other side effects of the medication include
facial flushing, headaches, bronchospasm, hypotension,
bradycardia, heart block, palpitations and chest pain.39
Other potential agents
Intravenous sildenafil, now commercially available, has
comparable efficacy to NO and may be an attractive alter-
native for testing pulmonary vascular reactivity, where NO is
not available.13 Sildenafil inhibits the breakdown of cGMP by
phosphodiesterase type 5, increasing the activity of the
endogenous nitric oxide in the pulmonary vasculature.
Multiple other vasodilator agents have been tested in
patients with PAH. The NIH registry included patients chal-
lenged with various medications during pulmonary vasodi-
lator testing. Systemic mean arterial pressure decreased
after the administration of nifedipine, nitroprusside and
prostacyclin. The mPAP did not decrease significantly after
any vasodilator, although PVR decreased with the adminis-
tration of nifedipine and prostacyclin. Cardiac output
increased after the administration of nifedipine and pros-
tacyclin. An insignificant trend towards increase in the mPAP
was observed after the administration of hydralazine.11
Calcium channel blockers were the agent of choice in
earlier studies,38 but their use during pulmonary vasodilator
testing has been abandoned due to the occurrence of
severe adverse effects and prolonged duration of the test,
attributed to their long half-lives.
Comparisons between recommended agents
NO versus epoprostenol
Morales-Blanhir et al. compared the diagnostic perfor-
mance of acute vasodilator testing using NO and room air
with epoprostenol in predicting the clinical outcome after 1
year of treatment with oral vasodilators (predominantlyCCBs). A vasodilator response was considered significant
when total PVR decreased more than 30% and mPAP more
than 20%. The acute effects of both agents in decreasing
mPAP were similar but epoprostenol increased CO further
and decreased PVR to a greater extent. The acute vasodi-
lator criteria were fulfilled by 26% of patients with each
agent, but only 15% of the patients had a significant vaso-
dilator effect with both agents. Interestingly, patients who
had a favorable response to oral vasodilators evidenced
a greater decrease in mPAP with NO than with epoproste-
nol, indicating who NO best identifies patients that will
respond to long-term CCB treatment.24
A study by Sitbon et al. compared incremental doses of NO
(10e40 ppm) mixed with room air versus epoprostenol in 35
patients with PAH. A vasodilator responsewas defined as a fall
in PVRof 30% ormore. Bothdrugs produced similar vasodilator
response (37% were responders to both medications).29
A retrospective study by Sitbon et al. showed that in
patients who have a positive vasodilator response, the
mPAP change was similar in patients tested with NO or
epoprostenol (approximately 33%). However PVR had
a greater decrease when epoprostenol was used instead of
NO (54 versus 44%).22
NO was compared with epoprostenol in patients with
IPAH. All the patients who responded to epoprostenol also
responded to inhaled NO. Although SVR decreased signifi-
cantly after epoprostenol infusion, it did not change with
the use of NO.53 A small study of 10 patients with PAH
evaluated vasoreactivity after the administration of NO,
epoprostenol and nifedipine. A positive vasodilatory
response was defined as a decrease by 20% or more in the
mPAP and PVR (60% of patients responded to all three
agents). In comparison with NO, epoprostenol and nifedi-
pine decreased arterial blood pressure, SVR and PaO2,
indicating a greater potential for side effects.56
Adenosine versus inhaled iloprost
Inhaled iloprost was compared with IV adenosine in iden-
tifying long-term CCB responders in patients with IPAH. Of
74 patients, 13.5% and 10.8% showed acute vasoreactivity
to iloprost and adenosine, respectively. All patients who
responded to adenosine, also responded to inhaled iloprost.
Both medications had similar capacity to identify long-term
responders to CCBs but iloprost was associated with better
tolerability. About 50% of vasoreactive patients with
inhaled iloprost were long term responders (12 months) to
CCBs.42
Inhaled NO versus inhaled iloprost
Inhaled NO was compared with inhaled iloprost in 35
patients. Iloprost produced a greater reduction in mPAP and
PVR along with a greater increase in CO and SvO2 when
compared with NO.50
Epoprostenol versus iloprost
Oxygen (3e8 L/m via nasal prongs), eposprostenol and ilo-
prost were compared in 21 patients with IPAH.57 Intrave-
nous epoprostenol caused a more prominent increase in CO
than inhaled iloprost but mPAP only decreased with the use
of oxygen or inhaled iloprost. Epoprostenol infusions
resulted in an increase in heart rate and a decrease in
490 A.R. Tonelli et al.arterial blood pressure. However, inhaled iloprost did not
alter these parameters. It is possible that IV epoprostenol
causes an excessive systemic vasodilation, leading to reflex
sympathetic activation that may counterbalance its bene-
ficial pulmonary vasodilatory effect.57
Inhaled iloprost combined with oral or IV sildenafil
The effects on hemodynamic parameters of the combina-
tion of inhaled iloprost and oral sildenafil were tested in
five patients with IPAH. The combination of iloprost plus
sildenafil achieved further reduction in mPAP than either
agent alone.68 These results were reproduced by another
study in patients with PAH (nZ 11) where the effects of
sildenafil were potentiated by combination with NO.73
Intravenous sildenafil (not commercially available)
augmented the pulmonary vasodilator effect of NO in
infants after cardiac surgery at the expense of systemic
hypotension.74
Adenosine versus epoprostenol
The acute effect of IV adenosine and IV epoprostenol were
compared in 10 patients with IPAH. Both medications
decreased PVR and increased CO without any effect on
mPAP.64
Areas of controversy
Pulmonary vasodilator testing may identify the presence of:
(1) vasoconstriction, (2) less fixed structural obstruction,
possibly present in earlier stages of disease when vascular
remodeling might not be the chief component of its path-
ophysiology, (3) a different variant of disease with slower
and more benign evolution.11,33,75
A positive test estimates the degree of vasoconstriction
at a given time, but does not predict the activity of the
underlying disease process. It is possible that those patients
who have a significant initial vasodilation but later fail
chronic CCB therapy have a more aggressive form of the
disease.14 Responders to vasodilator challenge may have
a better prognosis per se, independent of the treatment
administered.11 In support of this concept, two studies
showed that a decrease in PVR of more than 50% during
acute vasodilator test carries a better prognosis.23,26
However, a recent study, in abstract form, has not shownTable 6 Percentage of positive pulmonary vasodilator tests and
PAH type n
Anorexigen induced 127
Idiopathic 430
Connective tissue disease 166
HIV 123
Pulmonary veno-occlusive disease
and Pulmonary capillary
hemangiomatosis
34
Heritable 34
Porto-pulmonary 153
Congenital heart disease 41a better prognosis in the presence of pulmonary
vasoreactivity.25
It is relevant to mention that the recommended criteria
for acute response have not been prospectively validated.33
The study that motivated a change in the older criteria was
retrospective and performed in a referral center which
could have excluded patients that had a good response to
empirical treatment with CCBs in the community.22
Therefore, a precise definition of acute pulmonary vasodi-
lator response is still controversial.16
The revised criteria for a positive pulmonary vasodilator
test better identify long-term responders to CCBs, but still
fail to identify all the patients who will experience a long-
term CCB response.22,24 In a study by Sitbon et al. 5 of 38
patients who had long-term CCB response did not meet the
revised criteria for a positive pulmonary vasodilator test.22
It is unclear why some patients may have an initial
positive vasodilator test and do not respond to CCBs after
some time. Initial responders that had a sustained response
after a year of follow-up may have a different disease
process than the ones that did not show long term benefits
from the use of CCBs.26,70,71 It is interesting that a pulmo-
nary vasodilator test may be positive in patients receiving
CCBs, suggesting a possible added effect of vasodilatory
agents that have a different mechanism of action.27
It is unknown whether there is a benefit in repeating
pulmonary vasodilator testing in patients who showed an
initial positive vasodilator response, to ensure they are
sustained CCB responders. In our practice we do not
routinely repeat a vasodilator test in patients who were
initial responders, unless patients do not show clinical and/
or hemodynamic improvement.
Some patients can have a positive or a negative vaso-
reactivity test depending on the agent used for the test.44
No consensus exists regarding which medication is the best
agent for pulmonary vasodilatory testing. To improve the
reliability of the test we still need to identify the best agent
or combination of agents (including dose, delivery system,
duration of the study, etc.) capable of predicting long-term
CCB response. Once the previous is achieved, then the test
should be standardized and prospectively validated. We
understand that this is difficult to accomplish as PAH is
a rare disease and a low percentage of patients with PAH
are long-term CCB responders.long-term response to CCBs in PAH (modified from Ref. [76]).
% of Positive pulmonary
vasodilator tests
% of Long term
CCB responders
10.2 7.9
13.3 6.3
9 1.2
1.6 0.8
8.8 0
2.9 0
0.7 0
0 0
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patients with pulmonary hypertension other than IPAH?
A positive vasodilator test is infrequently observed in
patients with pulmonary arterial hypertension other than
IPAH and PAH associated with the use of anorexigens.16,22
Moreover a positive test in patients without IPAH is unlikely
to affect the choice of therapy.16
A preliminary report regarding the use of pulmonary
vasodilator test in patients with PAH other than IPAH,
showed that a positive test (fall in mPAP and PVR of more
than 20%) is rarely observed.76 Similarly, long term
responders to CCBs were rarely seen in conditions other
than idiopathic or anorexigen associated PAH.76 (Table 6).
A study by Rubenfire et al., in abstract form, revealed
that the frequency of positive pulmonary vasodilator tests
with inhaled NO was not significant different among
patients with idiopathic PAH (12.2%), PAH related to
scleroderma (13.2%) or PAH related to portal hypertension
(6.1%). The percentage of patients that responded long-
term to CCB therapy was not mentioned.25
BMPR2 (bone morphogenetic protein receptor type II)
nonsynonymous mutations, which are found more often in
heritable than idiopathic PAH, are associated with a nega-
tive vasodilator response.77 Three studies in patients with
IPAH and heritable PAH demonstrated that carriers are less
likely to have a positive pulmonary vasodilator test than
noncarriers of BMPR2 mutations.2,48,77 In the first study by
Elliott et al., a positive vasodilator test was identified in
only 3.7% of patients with BMPR2 variations, in contrast to
35% of positive tests in patients without BMPR2 muta-
tions.77,78 In the second study by Rosenzweig et al., BMPR2
mutation-positive patients were significantly less likely to
have a positive pulmonary vasodilator test than mutation
negative patients (4% versus 33%).48 Similarly, a study by
Sztrymf et al., demonstrated that the percentage of posi-
tive pulmonary vasodilator tests was lower in carriers
compared to noncarriers of BMPR2 mutations (1.5% versus
10.3%).79 The association between the presence of BMPR2
mutations and seldom positive pulmonary vasodilator
testing, may be partially explained by a more severe
hemodynamic compromise and advance disease stage at
the time of diagnosis of PAH, in carriers than in noncarriers
of BMPR2 mutations.45,48,79
Simmoneau et al., compared 62 PAH associated with the
use of anorexigens patients with 125 matched IPAH
patients. Both groups displayed similar baseline hemody-
namics, however the percentage of positive pulmonary
vasodilator tests (defined as a decrease in PVR and mPAP of
at least 20%) was significantly higher in the IPAH group (27%
versus 10%, p< 0.01).80
Patients with the limited cutaneous form of systemic
sclerosis (formerly referred as CREST syndrome), systemic
sclerosis or mixed tissue connective disease may experi-
ence an acute and sustained reduction in the PVR and mPAP
with vasodilators or immunosuppressive therapy, suggesting
a potential reversible vasoconstrictive element.81e87 Few
of these patients have a positive vasodilator response using
the new criteria for a positive test.76,81 Pulmonary edema
may occur in patients with limited cutaneous or systemic
sclerosis who have associated left ventricular dysfunc-
tion.86,88 Pulmonary edema has also been reported with the
use of NO in patients with limited cutaneous form ofsystemic sclerosis and normal PAOP, possible due to
a greater dilatation of precapillary pulmonary arteries
instead of postcapillary pulmonary venules, with increase
in pulmonary capillary hydrostatic pressure.89
Patients with HIV and PAH experienced a decrease in
PVR and mPAP, with an increase in CO, when challenged
with epoprostenol.90,91 However, very few of such patients
meet the current criteria for positive vasodilator response.
CCBs appear to provide no hemodynamic or clinical bene-
ficial effect in this group of patients.90,92
In Eisenmenger syndrome, CCBs produced no signifi-
cant changes in the hemodynamics when studied in 10
patients.93 In patients with PAH associated with portal
hypertension, no difference in the percentage of positive
pulmonary vasodilator tests were noted when compared
with patients with other forms of PAH.25,76,94 No long-term
CCB response has been observed in these two groups of PAH
patients.94
Although pulmonary vasodilator testing has been used in
patients with PAH other than IPAH of PAH associatedwith the
use of anorexigens, this test is rarely positive, and if positive,
seldom affects the choice of therapy.16,22 The most updated
evidence-based treatment algorithm in pulmonary arterial
recommends testing all patients with PAH, acknowledging
that patients with IPAH and anorexigen-induced PAH are
more likely to respond to CCB treatment.19
Can patients with negative acute vasodilator response
show long-term hemodynamic improvements?
Althougha great proportionof thepatientswith IPAHwill have
a negative vasodilator response, these patients may show
significant hemodynamic improvements (decline in the mPAP
and PVR) and survival benefits aftermonths of treatmentwith
prostaglandin analogs.27,40 These hemodynamic improve-
ments are most likely related to pulmonary vascular remod-
eling effects and reversal of pathological changes.10,40,95 It is
possible that clinical improvements may not always correlate
with favorable changes in hemodynamic parameters. In
patients treated with epoprostenol for a year, a significant
improvement in NYHA functional class was noted, even in the
presence of modest improvements in mPAP of 13%.71
Patients with PAH associated with HIV or Eisenmenger
syndrome showed significant hemodynamic responses after
treatment with bosentan.96,97 In patients with PAH associ-
ated with scleroderma spectrum of disease or portal
hypertension, epoprostenol produced hemodynamic
improvements.94,98
Why not use two agents to identify pulmonary
vasoreactivity?
Nitric oxide increases the levels of cGMP and causing
vascular smooth muscle vasodilation. This vasodilation
may be further increased by the addition of a second
pulmonary vasodilatory agent that increases cAMP (e.g.
adenosine or epoprostenol), thus raising the percentage of
positive vasoreactivity tests.99,100 This concept may be
supported by the results of the PACES study that showed
that in patients with PAH, the addition of sildenafil to
long-term epoprostenol therapy improved the hemody-
namic measurements (decrease in mPAP and increase in
cardiac output), exercise capacity, time to clinical wors-
ening and quality of life.101
Table 7 Advantages and limitations of pulmonary
vasodilator testing.
Advantages Limitations
 Identifies patients
who may benefit
from
CCB therapy.
 Possible recognition
of patients with
better prognosis.
 Prevents the use of
CCB therapy in
patients with a
negative pulmonary
vasodilator test,
avoiding adverse
effects of this
treatment.
 May help identify
patients with
pulmonary
veno-occlusive
disease or pulmo-
nary
capillary hemangio-
matosis (only when
epoprostenol is
used).
 Only positive in
a minority of
patients,
predominantly those
with IPAH or ano-
rexigen-induced
PAH.
 Some patients with
a positive pulmonary
vasodilator test may
not be long-term
CCB
responders.
 Potential adverse
effects depending on
the agent used.
 Time consuming
 Needs special equip-
ment and respiratory
therapist (when NO
is used).
 Increases the cost of
the test.
 Difficult
reimbursement.
492 A.R. Tonelli et al.It is unclear if the use of two vasodilator agents to
identify pulmonary vasoreactivity would be helpful in
identifying patients that may benefit from the use of
calcium channel blockers. Use of such testing to identify
PAH patients who might respond to combination therapy
has not been evaluated.
If patients are receiving CCBs, does CCB treatment need
to be held for pulmonary vasodilator testing?
It seems intuitive to stop CCBs 36 h before performing
a pulmonary vasodilator test, as concomitant use of these
agents may blunt the effects of the vasodilators tested.65 It
unknown whether some patients will have adverse conse-
quences with this approach, such as rebound pulmonary
hypertension.30,102 In a study that included patients treated
with CCBs, the short-term vasodilator response to adeno-
sine (measured by a decrease in PVR) was similar in the
group of patients receiving CCB treatment versus the group
of patients who were not receiving it.40 Another study
showed that in patients with IPAH that responded to CCBs
(reduction of 20% or more in PVR), the addition of intra-
venous adenosine further decreased mPAP and PVR.103
Therefore, the evidence available does not support stop-
ping CCBs before a pulmonary vasodilator test.
Can a negative vasodilator test become positive after
treatment?
As hemodynamics gradually improve in IPAH patients who
receive treatment with prostaglandin analogs,40,27 it is
possible that with time vessels may become vasoreactive
when challenged during pulmonary vasodilator testing, and
CCB treatment may become beneficial again. However, no
such successful therapy has been documented. A repeat
pulmonary vasodilator testing, in those patients who have
had an exceptional hemodynamic response to PAH therapy
may be considered, although there is no evidence to
support this approach.
A summary of the advantages and limitation of pulmo-
nary vasodilator testing is shown in Table 7.
Use of calcium channel blocker
Evidence supporting the use
Early experimental evidence in rat lungs suggested that
CCBs are capable of inhibiting hypoxic pulmonary vaso-
constriction.104 Shortly thereafter, a study indicated
that CCBs could be effective in patients with IPAH.105
Subsequently, CCBs were considered the first therapy
capable of providing a survival benefit in patients with
IPAH.11,27 No randomized controlled trial has been done
to confirm the beneficial effects of CCBs in the treat-
ment of IPAH, predominantly because of the rarity of
the condition.16 However, open label prospective studies
have shown a survival comparable to healthy individuals
with CCB treatment in vasoreactive IPAH patients. CCB
therapy in IPAH has not received regulatory approval
anywhere because of the paucity of supporting
evidence.
In 1987, a study in a few patients with IPAH reported
that high doses of CCBs (up to 720 mg/day of diltiazemand 240 mg/day of nifedipine) produced symptomatic
improvement and were effective in reducing PAP, PVR and
right ventricular hypertrophy in more than half of all
studied patients.30 The authors gave an initial dose of
60 mg of diltiazem or 20 mg of nifedipine followed by
consecutive hourly doses until development of side
effects or achieving a 50% and 33% reduction in PVR and
mPAP, respectively. The number of doses required to
significantly reduce the mPAP varied from 3 to 10. High
doses of CCBs were required to produce marked hemo-
dynamic responses. The need for larger doses suggests
a different sensitivity for CCBs on the pulmonary vascu-
lature in different disease stages.30
The same group treated a larger group of patients with
IPAH (nZ 64) with high doses of CCBs. Responders (27%),
defined by a fall in the pulmonary artery pressure and
vascular resistance of more than 20%, were treated for up
to 5 years. During follow-up, the majority experienced
clinical and hemodynamic improvement. More importantly,
there was a significant difference in survival favoring
responders versus non-responders.11
In a large retrospective study (nZ 557) in which IPAH
patients were treated with CCBs, after demonstrating
acute pulmonary vasoreactivity, long-term CCB responders
had a survival of 97% at an average follow-up of 7 years. On
the contrary, CCB non-responders had a survival of only 48%
at 5 years and several patients in this group were trans-
planted or started on prostaglandin analogs or endothelin
receptor antagonist therapy.22
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In patients with IPAH and positive pulmonary vasoreactivity
test, CCBs have a pulmonary vasodilator effectwith reduction
in the mPAP and increase in quality of life and survival.5,17
The role of CCBs in forms of PAH other than idiopathic
has not been thoroughly assessed as therapies that benefit
larger proportions of the PAH population have been
introduced.21
The current approach is to initiate CCBs if the patient
has a positive vasodilator test, adequate systemic blood
pressure (above 90 mmHg) and stable dyspnea in NYHA class
IeIV prior to initiation of therapy.19 (Fig. 2).
It is relevant to note that CCBs are inappropriately used in
a significant number of patients with PAH. This was evi-
denced by a registry of PAH, that included patients referred
to a tertiary care center from 1982 to 2006. This study
showed that 31% of the patients referredwere receiving CCBs
even when only 4.6% had a positive vasodilator challenge.41
More recently, preliminary data from the Quality Enhance-
ment Research Initiative (QuERI), measured in 782 patients
with PAH enrolled by United States specialist physicians
mostly from community sites, revealed that right heart
catheterization was performed in 90% of the patients. A total
of 15% of the patients included in the QuERI study were
receiving CCB therapy (46% specifically for PAH treatment).
Out of the patients treated for PAH with CCBs only 41.5% had
a pulmonary vasodilator test performed and only 13.2% had
a positive response.106,107 In the QuERI study, 49% of patientsFigure 2 Algorithm for the treatment of pulmonary arterial
hypertension (modified from 2007 ACCP Medical Therapy for
Pulmonary Arterial Hypertension guidelines5 and the 4th World
Symposium on Pulmonary Hypertension19).whowere receiving CCB treatment were doing so specifically
for PAH. It should be noted that in clinical practice, it is
common to encounter patients with PAH who are receiving
CCBs as treatment of Raynaud phenomenon or systemic
arterial hypertension, common comorbidities in PAH.
Type of CCB and mode of administration:
It is wise not to use CCBs with a prominent negative
inotropic effect as this practice can lead to adverse
hemodynamic effects in patients with PAH.16 The agents
commonly recommended are long-acting nifedipine, dil-
tiazem or amlodipine.19 The use of verapamil is discouraged
due to its negative inotropic effect.5
Calcium channel blockers are introduced cautiously
and progressively titrated to higher doses.16 The dose can
be initiated at 30 mg of nifedipine or 120 mg of diltiazem
per day. This dose should then be gradually increased over
the course of weeks to reach the maximal tolerated
daily dose (up to nifedipine 240 mg/day and diltiazem
900 mg/day).
Follow-up
Frequent monitoring of symptoms, functional capacity and
adverse effects is essential.21,23 As about half of patients
who had an initial positive pulmonary vasodilator test
would not experience long-term clinical benefits, close
follow-up is required to assure sustained benefits of CCB
therapy.10,22,44 An initial 3-month clinical assessment is
recommended. If functional NYHA class I or II has not been
achieved, then additional or alternative therapies are
suggested.19 (Fig. 2).
Contraindications
Calcium channel blockers are contraindicated in subjects
with hemodynamic instability, heart failure (cardiac index
below 2 l/min/m2 and RA pressure above 20 mmHg) or
previous adverse reactions to the medication.18,21 CCB
use, especially in patients with a negative pulmonary
vasodilator test and who have signs of right heart failure,
can lead to systemic side effects, worsening of the right
ventricular performance, pulmonary edema and
death.16,18,19,38,75,108e111
Conclusions
A positive pulmonary vasodilator test is observed in about
10e15% of patients with IPAH and only half of them will
experience long-term benefits with CCBs, suggesting that
there may be other factors determining long-term effec-
tiveness of CCBs. A positive vasodilator test is infrequently
observed in patients with PAH other than IPAH and PAH
associated with the use of anorexigens. There is no
consensus on the best agent to use for pulmonary vasodi-
lator testing, although inhaled NO is generally recom-
mended. A precise definition of positive test is still
controversial. It is unclear if a responsive pulmonary
vasculature has a more favorable prognosis regardless of
the use of CCBs. Patients that are started on CCB therapy
494 A.R. Tonelli et al.need to be carefully monitored both clinically and hemo-
dynamically to assure long-term CCB response.Conflict of interest
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